Close this search box.
Close this search box.


T2 Biosystems
101 Hartwell Avenue
Lexington, MA 02421
Phone: 781-457-1200
Fax: 781-357-3080

T2Biothreat Panel

Exceptional Biothreat Detection, Direct from Whole Blood

The FDA-cleared T2Biothreat® Panel is a direct-from-blood molecular diagnostic test that runs on the FDA-cleared T2Dx® Instrument and simultaneously detects six biothreat pathogens identified as threats by the U.S. Government, including the organisms that cause anthrax (Bacillus anthracis), tularemia (Francisella tularensis), glanders (Burkholderia mallei), melioidosis (Burkholderia pseudomallei), plague (Yersinia pestis), and typhus (Rickettsia prowazekii).

The T2Biothreat Panel is the first and only FDA-cleared product able to detect these six high-priority biothreat pathogens simultaneously, and the only multi-target biothreat product developed and manufactured by a U.S.-owned company. The U.S. clinical evaluation to support the FDA 510(k) submission included testing of the T2Biothreat Panel at MRIGlobal, a Biosafety Level 3 laboratory specializing in biothreat pathogens, and Oschner Medical Center.

T2MR® Technology: The T2Biothreat Panel utilizes the same T2MR® Technology and T2Dx Instrument as the T2Bacteria® and T2Candida® Panels – the first and only FDA-cleared and CE-marked panels for detection of sepsis-causing bloodstream infections direct from a patient’s blood sample, without requiring blood culture results.

T2Biothreat Panel

To learn more about the T2Biothreat Panel, please schedule a meeting today.
  1. Pearson, A., et al. Analytical testing of a rapid, direct from patient sample assay for biothreat pathogens using a fully automated assay platform. Poster ASM 2022.
  2. Administration for Strategic Preparedness & Response (ASPR) PHEMCE High Priority Biological Threats List.